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Introduction
Nonalcoholic fatty liver disease (NAFLD) is recognized
as the most common cause of chronic liver disease in many
countries. NAFLD does not progress to more severe liver
disease in most cases, but the liver occasionally exhibits fi-
brosis and necroinflammation, indicating the presence of
nonalcoholic steatohepatitis (NASH).1, 2 The recent increase
in the number of patients with NAFLD has necessitated the
study of treatment options which include dietary interven-
tions. However, to date, no standardized treatments have
been approved.3-5 Based on the "two-hit" model of NASH
pathogenesis,6, 7 the strategies to inhibit NAFLD or NASH
progression consist of adipose tissue and oxidative stress
reduction, insulin resistance improvement and lipid profile
optimization.3 An altered dietary macronutrient composi-
tion, i.e., a greater intake of monounsaturated fatty acids,
would be recommended because saturated fatty acids have
deleterious effects on liver function.7, 8
Although the studies of the effects of different diets on
NAFLD or NASH have been seldom performed in human,
a Mediterranean diet has been proposed for the prevention
of metabolic syndrome including hypertension and cardio-
vascular diseases. The main part of its beneficial effect is
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Oleuropein, the active constituent of olive leaf extract, possesses anti-oxidant, hypoglycemic, and hypolipidemic activities.
We aimed to assess whether the effect of olive leaf extract on hepatic fat accumulation is preventive or therapeutic. Sprague-
Dawley (SD) rats were fed a high-fat diet with (ODOD group) or without (HDHD group) olive leaf extract (1,000 mg/kg diet) for
38 weeks. Another group of rats were fed a high-fat diet for 23 weeks, followed by a high-fat diet with olive leaf extract (1,000
mg/kg diet) for 15 weeks (HDOD group). Serology, histopathology, anti-oxidative activity, and liver fatty acid synthesis were
compared to those fed a standard diet (LDLD group) at 26 and 41 weeks of age. The serum levels of total cholesterol,
triglyceride and aspartate aminotransferase tended to be lower in the ODOD group as compared to the HDHD and HDOD
groups, although there were no significant differences. Histopathologically, hepatic steatosis tended to be less evident in the
HDOD and ODOD groups as compared to the HDHD group, and lobular inflammation was not observed in the ODOD group
at 26 weeks of age. Hepatic thioredoxin-1 staining tended to be less evident in the ODOD group than in the HDHD and HDOD
groups at 41 weeks of age. There were no significant differences in hepatic lipogenic enzyme activities between the ODOD
group and HDHD/HDOD groups. Our data suggest that olive leaf extract had a preventive, rather than therapeutic, effect on
hepatic steatohepatitis in SD rats fed a high-fat diet.
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thought to be a high supply of energy coming from mono-
unsaturated fatty acids, mainly from olive oil.5, 9 Olive prod-
ucts constitute many phenolic compounds such as oleuropein,
hydroxytyrosol and tyrosol.10 Most of these possess an anti-
oxidant ability, which may have a beneficial effect on
metabolic syndrome, and also, on NAFLD or NASH.5, 8 In
this context, we recently reported that an olive leaf extract-rich
diet had a preventive effect on the occurrence of NASH or
NAFLD, and this effect was presumably due to the anti-
oxidative activity in the spontaneous NASH model of spon-
taneously hypertensive/NIH-corpulent [SHR/NDmcr-cp(cp/cp)]
rats.11 This strain has a genetic background from SHR and
also a genetic mutation in the leptin receptor gene.12 However,
such a genetic background is not common in humans with
NAFLD. Moreover, whether the effect of olive leaf extract
on NASH or NAFLD is preventive or therapeutic remains
unclear. The aim of the present study was to evaluate the
preventive or therapeutic effects of olive leaf extract on he-
patic fat accumulation in Sprague-Dawley (SD) rats fed a
high-fat diet, since high-fat diet can induce NAFLD or
NASH in SD rats.13
Materials and Methods
Animals and experimental design
Three-week-old male SD rats (n=37) were purchased from
Nippon SLC (Hamamatsu, Japan). The rats were housed in
individual cages that were kept in a room maintained at 22-
24°C with 50-60% relative humidity and a 12-hour light/12-
hour dark cycle. Rats were randomly divided into four
groups: low fat diet-low fat diet (LDLD) group (n=10), fed
a low-fat (standard) diet (LFD) containing 10% fat (5.5%
of soybean oil and 4.4% of lard, kilocalories) (D12450B;
Research Diets, New Brunswick, NJ, USA); high fat diet-
high fat diet (HDHD) group (n=10), fed a high-fat diet
(HFD) containing 45% fat (5.5% of soybean oil and 39.4%
of lard, kilocalories) (D12451; Research Diets); high fat
diet-olive containing high fat diet (HDOD) group (n=5),
fed a HFD for 23 weeks followed by a HFD containing
0.1% olive leaf extract (OD) (D08080103; Research Diets)
for 15 weeks; and olive containing high fat diet- olive con-
taining high fat diet (ODOD) group (n=12), fed an OD. The
olive leaf extract (containing 35% oleuropein, 30-40% car-
bohydrate, 0-5% protein, 0-10% other polyphenols, and ap-
proximately 10% unknown components) was obtained from
Eisai Food & Chemical Co. (Tokyo, Japan) and the OD
was manufactured by Research Diets. The compositions of
LFD, HFD and OD are shown in Table 1. In the LDLD,
HDHD and ODOD groups, 5 rats each were sacrificed at
26 weeks of age in order to investigate the histopathology
of the liver, and the other rats (5 LDLD, 5 HDHD, 5
HDOD and 7 ODOD) were sacrificed at 41 weeks of age
under anesthesia (pentobarbital sodium) after 20-hour fast-
ing (Figure 1).
In general, the rats had free access to food and water in
both 12-hour light and 12-hour dark periods. However, in
30






















































































































































LFD, low-fat (standard) diet; HFD, high-fat diet; OD, HFD supplemented
with 0.1% olive leaf extract.
Figure 1. Experiment design. LFD, low-fat (standard) diet; HFD,
high-fat diet; OD, HFD supplemented with 0.1% olive leaf ex-
tract.
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order to avoid a significant difference in body weights among
groups, daily food intake was maintained at 22 g of LFD
from 10 to 41 weeks of age in the LDLD group, 22 g of HFD
from 10 to 16 weeks of age and 20 g of HFD from 17 to 41
weeks of age in the HDHD and HDOD groups, 22 g of OD
from 10 to 34 weeks of age, and 20 g of OD from 35 to 41
weeks of age in the HDOD and ODOD groups. Daily en-
ergy intake and body weights were monitored during the
study. Systolic blood pressure was measured in conscious rats
by the indirect tail-cuff method at 16 and 34 weeks of age.
All rats were sacrificed under anesthesia at 26 or 41 weeks
of age, and blood samples were taken from the inferior vena
cava or heart for measurement of serum glucose, insulin,
total cholesterol, triglyceride, aspartate aminotransferase
(AST), and alanine aminotransferase (ALT) levels. Serum
samples obtained were kept at -20°C until analysis. The
epididymal fat pads were removed and weighed. The livers
were also removed, washed in a cold saline solution, and
weighed. Liver portions (approximately 5 g) were fixed in
10% neutral buffered formalin for the histopathological ex-
aminations. Other liver portions (approximately 2 g) were
diced and suspended in 0.25 M sucrose in 10 mM Tris-HCl
(pH 7.4) and 1 mM ethylenediaminetetraacetic acid (EDTA)
(HG buffer). The mixture was homogenized using a Potter
homogenizer and centrifuged at 700 x g for 10 min at 4°C.
The supernatants were again centrifuged at 10,000 x g for
10 min at 4°C and the pellets were suspended in HG buffer
(mitochondrial fraction). The supernatants were further
centrifuged at 125,000 x g for 60 min at 4°C and the pellets
were again suspended in HG buffer (microsomal fraction).
The supernatants were denoted as the cytosolic fraction.
Each fraction was assessed for enzymatic activity. All pro-
cedures were performed in accordance with the Guidelines
for Animal Experimentation and approved by the Animal
Usage Committee of University of Nagasaki, Japan.
Serum biochemical analysis
Serum glucose levels were determined by the mutarotase
and glucose oxidase method (Glucose C II test Wako, Wako
Pure Chemical Industries, Osaka , Japan). Serum insulin levels
were measured using a commercially available ELISA kit
(Morinaga Institute of Biological Science, Kanagawa, Japan).
Serum total cholesterol and triglyceride levels were measured
by the cholesterol oxidase DAOS method (Cholesterol E test
Wako, Wako Pure Chemical Industries) and the GPO DAOS
glycerol method (Triglyceride E test Wako, Wako Pure
Chemical Industries), respectively. Serum AST and ALT levels
were estimated by an automatic analyzer (SRL, Tokyo, Japan).
Histopathological examinations
After fixation in neutral buffered formalin, the liver was sec-
tioned and processed for routine hematoxylin-eosin (HE)
staining for histopathological examination. All histopathological
examinations were performed by a pathologist (K.T.) who
was blinded to the experimental and serological data.
Histopathological findings were scored using the NASH
Clinical Research Network Scoring System based on four
semi-quantitative factors: steatosis (0-3), lobular inflamma-
tion (0-3), hepatocyte ballooning (0-2), and fibrosis (0-4) as
previously described.14 The NAFLD activity score (NAS)
was defined as the unweighted sum of the scores for
steatosis, lobular inflammation, and hepatocyte ballooning;
thus, scores ranged from 0 to 8. A NAS of 0 to 2 was con-
sidered not diagnostic of steatohepatitis, and scores of 5 or
greater were diagnostic of steatohepatitis.14
For the immunohistochemical analysis of thioredoxin
(Trx), which is a marker of oxidative stress,15, 16 an en-
hanced immunostaining method using an enzyme-labeled
polymer was performed on deparaffinized liver sections.
Anti-mouse recombinant antibody against Trx-1 (Redox
Bioscience, Kyoto, Japan; 1:100 dilution) was used as the
primary antibody. Instead of primary antibody, normal rab-
bit serum was used as a negative control. For the following
reactions, Envision-PO for mouse monoclonal antibodies
(DAKO, Glostrup, Denmark) was used as the secondary
antibody. The intensity of cytosolic or nuclear staining of
Trx-1 in hepatocytes, hepatic sinusoidal endothelial cells
and Kupffer cells in the liver section was classified into
three grades as follows: grade 0, 0-10% of cells had posi-
tive staining; grade 1, 10-50% of cells had positive stain-
ing; grade 2, more than 50% of cells had positive staining.
Assays for enzyme activity
The activity of hepatic fatty acid synthase (FAS) in the
cytosolic fraction was determined spectrophotometrically by
the method of Kelley et al.17 Malic enzyme activity in the
cytosolic fraction was assayed by a previously reported
method.18 Glucose-6-phosphate dehydrogenase (G6PDH)
activity in the cytosolic fraction was measured by the method
of Kelley et al.19 Carnitine palmitoyltransferase (CPT) activity
in the mitochondrial fraction was confirmed spectrophotometrically
by the release of CoA-SH from palmitoyl-CoA using the
general thiol regent 5, 5'-dithiobis, as described previously.20
Phosphatidic acid phosphohydrolase (PAP) activity in the
cytosolic and microsomal fractions was measured by the
method of Walton and Possmayer.21 Protein concentrations
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were determined by the method of Lowry et al.22
Statistical analysis
All values were expressed as mean ± standard error
(SE). Differences between groups were tested for statistical
significance using one-way analysis of variance (ANOVA)
followed by Bonferroni multiple comparison test, Student's
t-test, chi-square test, or Fisher's exact probability test. All
analyses were performed using the SPSS 16.0J software
program (SPSS, Inc., Chicago, IL, USA) on a Windows
computer. P < 0.05 was considered significant.
Results
Food intake, body weight, systolic blood pressure, liver
weight/rat weight ratio, and epididymal fat pad volume
In rats that were sacrificed at 26 weeks of age, the cu-
mulative energy intake during the 23 weeks of the study
was not significantly different among groups. In rats that
were sacrificed at 41 weeks of age, the cumulative energy
intake in the HDOD group during the 38 weeks was signifi-
cantly larger than that in the LDLD group (p=0.014), de
spite the limitation of the daily food intake. The body weight
at 26 weeks of age was not significantly different among
groups. On the other hand, the body weight at 41 weeks of
age in the LDLD group was significantly lower than that in
the other groups (p=0.004). There were no significant dif-
ferences in systolic blood pressure among groups at both 16
and 34 weeks of age. The liver weight/body weight ratio
was not significantly different among groups at both 26 and
41 weeks of age. The relative weight of the epididymal fat
pad (g/100 g of body weight) was not significantly different
among groups at both 26 and 41 weeks of age (Table 2).
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LDLD HDHD HDOD ODOD
Parameter group group group group
Cumulative energy intake (kcal)
26 weeks of age 11812 ± 238 (n=5) 13410 ± 535 (n=5) - 13043 ± 414 (n=5)
41 weeks of age 21010 ± 345a (n=5) 22783 ± 492 (n=5) 24287 ± 567a (n=5) 23319 ± 768 (n=7)
Body weight (gram)
26 weeks of age 562 ± 12 (n=5) 620 ± 34 (n=5) - 606 ± 16 (n=5)
41 weeks of age 613 ± 6b,c,d (n=5) 684 ± 9b (n=5) 711 ± 21c (n=5) 680 ± 18d (n=7)
Systolic blood pressure (mmHg)
16 weeks of age 148 ± 6 (n=5) 125 ± 8 (n=5) - 130 ± 4 (n=5)
34 weeks of age 127 ± 6 (n=5) 134 ± 9 (n=5) 146 ± 9 (n=5) 144 ± 5 (n=7)
Liver weight/rat weight ratio (%)
26 weeks of age 3.0 ± 0.2 (n=5) 2.5 ± 0.1 (n=5) - 2.9 ± 0.2 (n=5)
41 weeks of age 2.8 ± 0.1 (n=5) 2.3 ± 0.1 (n=5) 2.5 ± 0.1 (n=5) 2.4 ± 0.1 (n=7)
Relative weight of epididymal fat pad (gram/100gram of body weight)
26 weeks of age 2.7 ± 0.1 (n=5) 2.7 ± 0.3 (n=5) - 2.7 ± 0.1 (n=5)
41 weeks of age 2.5 ± 0.1 (n=5) 2.9 ± 0.2 (n=5) 2.8 ± 0.2 (n=5) 2.7 ± 0.2 (n=7)
Serum glucose (mg/dL)
26 weeks of age 205 ± 18 (n=5) 246 ± 29 (n=4) - 290 ± 59 (n=5)
41 weeks of age 200 ± 42 (n=5) 158 ± 15 (n=5) 169 ± 10 (n=5) 188 ± 16 (n=7)
Serum insulin (ng/mL)
26 weeks of age 5.0 ± 1.2 (n=5) 5.9 ± 0.9 (n=4) - 7.2 ± 0.5 (n=5)
41 weeks of age 4.8 ± 0.4 (n=5) 5.4 ± 1.2 (n=5) 4.7 ± 0.6 (n=5) 5.3 ± 0.7 (n=7)
Serum total cholesterol (mg/dL)
26 weeks of age 109 ± 13 (n=5) 91 ± 8 (n=4) - 74 ± 4 (n=5)
41 weeks of age 123 ± 18 (n=5) 99 ± 5 (n=5) 93 ± 11 (n=5) 75 ± 14 (n=7)
Serum triglyceride (mg/dL)
26 weeks of age 191 ± 33 (n=5) 89 ± 23(n=4) - 139 ± 39 (n=5)
41 weeks of age 221 ± 43e (n=5) 134 ± 7 (n=5) 113 ± 27 (n=5) 84 ± 16e (n=7)
Serum AST (IU/L)
26 weeks of age 218 ± 78 (n=4) 96 ± 1 (n=2) - 84 ± 7 (n=4)
41 weeks of age 147 ± 46 (n=5) 94 ± 18 (n=5) 118 ± 29 (n=5) 87 ± 8 (n=7)
Serum ALT (IU/L)
26 weeks of age 161 ± 78 (n=4) 45 ± 10 (n=2) - 42 ± 5 (n=4)
41 weeks of age 109 ± 46 (n=5) 44 ± 7 (n=5) 72 ± 28 (n=5) 50 ± 9 (n=7)
Values are means ± SE.
a-e, Superscripts indicate significant differences as follows: a p=0.014, b p=0.049, c p=0.004, d p=0.043, e p=0.006.
AST, aspartate aminotransferase; ALT, alanine amintransferase.
The definitions of LDLD, HDHD, HDOD, and ODOD group: see text in Materials and Methods section.
Table 2. Food intake, body weight, systolic blood pressure, liver weight/rat weight ratio, and epididymal fat pad volume,
and serum biochemical parameters
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Serum biochemical parameters
All serum biochemical data failed to be obtained in one
rat in the HDHD group at 26 weeks of age, because insuf-
ficient serum samples were taken. Serum AST and ALT
levels were not measured in one rat in the LDLD group,
two rats in the HDHD group, and one rat in the ODOD
group at 26 weeks of age, because of inadequate serum
sample volumes.
There were no significant differences in serum levels of
glucose, insulin, total cholesterol, AST, and ALT among
the three (26 weeks of age) or four (41 weeks of age)
groups. The serum triglyceride levels in the LDLD group
were higher than those in the ODOD group at 41 weeks of
age (Table 2).
Histopathological observation
Representative histopathological results in the livers of
the LDLD, HDHD and ODOD groups at 26 weeks of age,
and LDLD, HDHD, HDOD and ODOD groups at 41 weeks
of age are shown in Figures 2 and 3, respectively. At 26
weeks of age, there were no significant differences in
score/grade of hepatic steatosis, lobular inflammation,
hepatocyte ballooning, NAS, and fibrosis among the three
groups. The scores of hepatic steatosis, lobular inflamma-
tion, hepatocyte ballooning, and NAS tended to be higher
in the HDHD group as compared to the LDLD group, al-
though the differences were not statistically significant.
Lobular inflammation and NAS of 5 points or greater were
not observed in the ODOD group. At 41 weeks of age, the
score of steatosis in the HDHD group was significantly
higher than that in the LDLD group (p=0.03). The scores of
hepatocyte ballooning and NAS also tended to be higher in
the HDHD group as compared to the LDLD group, al-
though the differences were not statistically significant. In
the HDOD and ODOD groups, the scores of steatosis,
hepatocyte ballooning, and NAS tended to be higher than
those in the LDLD group, although the differences were not
statistically significant (Table 3).
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Figure 2. Representative histopathology (HE stain) of rat liver in LDLD, HDHD, and ODOD rats at 26
weeks of age. (A) Fatty change, lobular inflammation, hepatocyte ballooning, and fibrosis were seldom
seen in the LDLD group (original magnification x100). (B) Moderate micro- or macrovesicular fatty
change was seen in periportal area. Mild lobular inflammation and moderate hepatocyte ballooning with-
out fibrosis were also seen in the HDHD group (original magnification x400). (C) Mild fatty change
(perivenular) and hepatocyte ballooning without lobular inflammation and fibrosis were seen in the
ODOD group (original magnification x100). P, portal tracts; CV, central vein.
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Representative immunohistochemistry for Trx-1 in the
liver of the LDLD, HDHD and ODOD groups at 26 weeks
of age, and LDLD, HDHD, HDOD and ODOD groups at
41 weeks of age are shown in Figures 4 and 5, respectively.
Although the differences were not statistically significant,
the grades of Trx-1 staining in the HDHD and ODOD groups
tended to be lower than those in the LDLD group at 26
weeks of age. In contrast, the grades of Trx-1 staining in
the HDHD, HDOD, and ODOD groups tended to be higher
than those in the LDLD group at 41 weeks of age. However,
4 out of 7 (57%) rats in the ODOD group were grade 2,
whereas 4 out of 5 (80%) rats in the HDHD and HDOD
groups exhibited grade 2 Trx-1 staining (Table 3).
Hepatic lipogenic enzyme activity
The activity of hepatic FAS, the enzyme required in
fatty acid synthesis, was higher in the LDLD group than in
the HDHD and ODOD groups at 26 weeks of age, although
there were no significant differences among LDLD, HDHD,
HDOD and ODOD groups at 41 weeks of age. The activity
of malic enzyme, the enzyme involved in the synthesis of
long-chain fatty acids and that supplies the NADPH re-
quired for palmitate synthesis, was also higher in the LDLD
group than in the HDHD and ODOD groups at 26 weeks of
age, although there were no significant differences among
the four groups at 41 weeks of age. The activity of G6PDH,
the rate-limiting enzyme of the pentose phosphate pathway
in glucose metabolism that generates NADPH and regu-
lates lipogenesis, was higher in the LDLD group than in the
HDHD group at 26 weeks of age, and in the other three
groups at 41 weeks of age. The activities of hepatic CPT
(the rate-limiting step in fatty acid oxidation) and PAP (the
enzyme that catalyzes the penultimate and rate-limiting step
in triglyceride synthesis) were not significantly different
between groups at both 26 and 41 weeks of age (Table 4).
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Figure 3. Representative histopathology (HE stain) of rat liver in LDLD, HDHD, HDOD, and ODOD
rats at 41 weeks of age. (A) Mild fatty change without lobular inflammation, hepatocyte ballooning, and
fibrosis was seen in the LDLD group (original magnification x100). (B) Moderate micro- or
macrovesicular fatty change and mild hepatocyte ballooning without lobular inflammation and fibrosis
were seen in the HDHD group (original magnification x400). (C) Fatty change, lobular inflammation,
hepatocyte ballooning, and fibrosis were seldom seen in the HDOD group (original magnification x100).
(D) Mild fatty change without lobular inflammation, hepatocyte ballooning, and fibrosis was seen in the
ODOD group (original magnification x100). P, portal tracts; CV, central vein
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At 26 weeks of age LDLD HDHD ODOD
group group group
Score/grade (n=5) (n=5) (n=5) p
Steatosis
0 2 1 0
1 3 1 3
2 0 3 2 n.s.
Lobular inflammation
0 3 1 5
1 2 4 0 n.s.
Hepatocyte ballooning
0 4 0 1
1 1 4 3
2 0 1 1 n.s.
NAFLD activity score
0-2 5 2 4
3-4 0 2 1
5-8 0 1 0 n.s.
Fibrosis
0 5 5 5 n.s.
Trx-1 staining
0 0 1 2
1 3 4 3
2 2 0 0 n.s.
At 41 weeks of age LDLD HDHD HDOD ODOD
group group group group
Score/grade (n=5) (n=5) (n=5) (n=7) p
Steatosis
0 1 0 0 0
1 4 0 2 3
2 0 5 3 4 0.030
Lobular inflammation
0 2 3 2 3
1 2 2 3 4
2 1 0 0 0 n.s.
Hepatocyte ballooning
0 5 2 3 4
1 0 3 2 3 n.s.
NAFLD activity score
0-2 5 1 2 3
3-4 0 4 3 4 n.s.
Fibrosis
0 5 4 3 6
1A 0 1 2 1 n.s.
Trx-1 staining
0 2 0 0 1
1 3 1 1 2
2 0 4 4 4 n.s.
Table 3. Histopathological assessment of steatosis, lobular inflammation, hepatocyte balloon-
ing, NAFLD activity score (NAS), fibrosis, and thioredoxin (Trx)-1 staining
* Scores are according to the NASH Clinical Research Network Scoring System.14 n.s., not significant.
The definitions of LDLD, HDHD, HDOD, and ODOD group: see text in Materials and Methods section.
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Figure 4. Representative immunohistochemistry for thioredoxin (Trx)-1 in livers from LDLD, HDHD, and
ODOD rats at 26 weeks of age. (A) More than 50% of hepatocytes, hepatic sinusoidal endothelial cells and
Kupffer cells had positive staining in the LDLD group. (B and C) Moderate (10-50%) cytosolic or nuclear
staining of such cells was seen in the HDHD and ODOD groups (original magnification x400).
Figure 5. Representative immunohistochemistry for thioredoxin (Trx)-1 in livers from LDLD, HDHD,
HDOD, and ODOD rats at 41 weeks of age. (A and D) Moderate (10-50%) cytosolic or nuclear staining of
hepatocytes, hepatic sinusoidal endothelial cells and Kupffer cells was seen in the LDLD and ODOD groups.
(B and C) More than 50% of such cells had positive staining in the HDHD and HDOD groups (original mag-
nification x400).
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Discussion
Epidemiological studies have shown that a Cretan Mediterranean
diet, characterized by the high consumption of olive oil, fruits,
vegetables, cereals, and legumes, lowers the risk of coronary
heart disease, cancer, and mortality rates for all causes.23, 24
Olive products constitute a rich source of polyphenols, such
as oleuropein, that scavenge free radicals and inhibit the
chemical oxidation of low-density lipoprotein.25 According
to the average consumption of olive drupes and olive oil in
the Mediterranean basin, the estimated polyphenol (mainly
originating from the hydrolysis of oleuropein) consumption
is up to 100 mg/day.22 Although oleuropein is present through-
out the olive tree and in olive oil, the olive leaf is the richest
source of this compound (60-90 mg/g dry weight).26 Oleuropein,
the principal active constituent of olive leaf and unprocessed
olive drupes of Olea europaea, possesses a wide range
of pharmacologic properties including anti-oxidant, anti-
inflammatory, hypoglycemic, hypolipidimic, hypotensive,
and anti-viral activities.10, 25-33 The direct effect of olive oil or
oleuropein on NAFLD is not fully understood,8, 34 but we re-
cently reported that diets rich in olive leaf extract (the rich-
est source of oleuropein), containing more than 1,000
mg/kg, had a preventive effect on the occurrence of NASH
in SHR/NDmcr-cp(cp/cp) rats.11
To determine whether olive leaf extract (containing more
than 1,000 mg/kg diet) has a preventive or therapeutic ef-
fect on NASH or NAFLD in SD rats fed high-fat diets, we
evaluated serum biochemical parameters and liver histol-
ogy in rats treated with a variety of high-fat diet regimes
(LDLD, HDHD, HDOD, and ODOD) in the present study.
In the LDLD group, there were several unexpected results
such as higher tendency in the serum levels of total choles-
terol, triglyceride, AST, and ALT, despite the lower body
weight than in other groups (Table 2). Overall, there were
no significant differences in serum levels of biochemical
parameters including glucose, insulin, total cholesterol,
triglyceride, AST, and ALT among the three (26 weeks of
age) or four (41 weeks of age) groups, with the exception
of higher serum triglyceride levels in the LDLD group
compared to those in the ODOD group at 41 weeks of age.
However, the serum levels of total cholesterol, triglyceride
and AST tended to be lower in the ODOD group as com-
pared to the HDHD and HDOD groups, although there
were no significant differences. These results suggest that
olive leaf extract has a preventive effect on the develop-
ment of a dyslipidemic state rather than a therapeutic effect.
Histopathologically, definitive NASH was uncommon in
the HDHD group at both 26 and 41 weeks of age.
However, when comparing the HDHD and LDLD groups,
the score of hepatic steatosis tended to be higher at 26
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LDLD HDHD HDOD ODOD
Enzyme group group group group
FAS activity (nmol/min/mg protein)
26 weeks of age 17.5 ± 2.2a,b 4.1 ± 1.3a - 2.9 ± 0.7b
41 weeks of age 3.0 ± 0.8 3.1 ± 0.2 4.0 ± 1.4 1.9 ± 0.9
Malic enzyme activity (nmol/min/mg protein)
26 weeks of age 54.4 ± 6.4c,d 22.3 ± 3.7c - 29.6 ± 5.0d
41 weeks of age 37.3 ± 6.4 29.1 ± 4.8 24.9 ± 4.1 25.7 ± 3.3
G6PDH activity (nmol/min/mg protein)
26 weeks of age 66.6 ± 11.6e 19.7 ± 3.2e - 34.0 ± 9.1
41 weeks of age 68.5 ± 11.2f,g,h 35.6 ± 3.2f 37.6 ± 7.5g 25.3 ± 3.8h
CPT activity (nmol/min/mg protein)
26 weeks of age 1.6 ± 0.3 2.9 ± 0.8 - 2.6 ± 1.3
41 weeks of age 1.3 ± 0.2 0.7 ± 0.1 1.6 ± 0.4 2.1 ± 0.8
PAP activity (nmol/min/mg protein)
26 weeks of age 32.0 ± 12.8 18.8 ± 1.9 - 17.4 ± 1.8
41 weeks of age 6.9 ± 1.0 8.9 ± 1.2 8.7 ± 1.4 12.2 ± 2.1
Values are means ± SE.
a-h, Superscripts indicate significant differences as follows: a p<0.001, b p<0.001, c p=0.003, d p=0.016, e p=0.008, f p=0.023, g p=0.036,
h p=0.001.
FAS, fatty acid synthase; G6PDH, glucose-6-phosphate dehydrogenase; CPT, carnitine palmitoyltransferase; PAP, phosphatidic acid
phosphohydrolase.
The definitions of LDLD, HDHD, HDOD, and ODOD group: see text in Materials and Methods section.
Table 4. Hepatic lipogenic enzyme activities
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weeks of age, and was significantly higher in the HDHD
group at 41 weeks of age. Conversely, the score of hepatic
steatosis tended to be lower in the HDOD and ODOD
groups as compared to the HDHD group at both 26 and 41
weeks of age. These results would indicate that olive leaf
extract has a preventive or therapeutic effect on hepatic fat
accumulation. It was noted that lobular inflammation was
not observed in the ODOD group at 26 weeks of age, sug-
gesting that olive leaf extract possesses the preventive ef-
fect on hepatic inflammation.
We also investigated the mechanism of olive leaf extract
effects, including its anti-oxidative activity and its altera-
tion of fatty acid metabolism in the liver. Oxidative stress
may contribute to the pathogenesis of NASH.1 Furthermore,
an imbalance in the influx of free fatty acids to the liver,
free fatty acid -oxidation, hepatic secretion of triglyceride-
rich lipoproteins, and lipid peroxidation can lead to the de-
velopment of hepatic steatosis in NAFLD or NASH.6
Sumida et al. reported that the level of serum Trx-1, a
redox-active protein, was a marker of NASH.35 Trx-1 plays
a crucial role in reduction/oxidation regulation in signal
transduction and is secreted from cells in response to oxida-
tive stress. Up-regulation of Trx-1 in chronic liver diseases,
as well as malignant diseases, human immunodeficiency
virus infection and cardiovascular disorders is well de-
scribed. However, whether Trx-1 contributes to or prevents
the pathology of such conditions is not always clear.15, 16
Moreover, hepatic Trx levels did not correlate with serum
Trx levels because hepatic Trx consists of both reduced and
oxidized forms whereas only the oxidized form is present
in serum.36 In our previous study, hepatic Trx-1 expression
in SHR/NDmcr-cp rats was more evident in rats fed an
olive leaf extract-rich diet than in rats fed an olive leaf ex-
tract-scarce diet; suggesting that a down-regulation of Trx-
1 expression in response to oxidative stress is probably due
to the exhaustion of tissue Trx secretion to the extracellular
space by chronic exposure to oxidative stress.11 In contrast,
no differences were observed in hepatic Trx-1 staining be-
tween the HDHD group and ODOD or HDOD groups in
the present study. The reason for these discrepancies is un-
clear, but we should consider that a rat strain-specific ge-
netic mechanism may be involved in Trx regulation (SHR
vs SD rats). Interestingly, hepatic Trx-1 staining in the
HDHD group tended to be less evident at 26 weeks of age,
and more evident at 41 weeks of age as compared to the
ODOD and HDOD groups. The reason for these apparent
discrepancies is also unclear, but it suggests that influence
of aging (26 vs 41 weeks of age) should be investigated. In
the present study, hepatic fatty acid metabolism analysis
revealed that there were no significant differences in the ac-
tivities of hepatic FAS, malic enzyme, G6PDH, CPT and
PAP between HDHD group and ODOD/HDOD groups at
both 26 and 41 weeks of age. These results suggest that
olive leaf extract has little effect on hepatic fatty acid me-
tabolism, as reported in our previous study,11 although the
activities of FAS (26 weeks of age), malic enzyme (26
weeks of age) and G6PDH (26 and 41 weeks of age) were
up-regulated in the LDLD group.
In summary, the serum levels of total cholesterol, triglyceride
and AST tended to be lower in the ODOD group as com-
pared to the HDHD and HDOD groups, although there
were no significant differences. Histopathologically, he-
patic steatosis tended to be less evident in the HDOD and
ODOD groups as compared to the HDHD group, and lobu-
lar inflammation that is an important finding suggestive
NASH was not observed in the ODOD group at 26 weeks
of age. Hepatic Trx-1 staining tended to be less evident in
the ODOD group than in the HDHD and HDOD groups at
41 weeks of age. There were no significant differences in
hepatic lipogenic enzyme activities between the ODOD
group and HDHD/HDOD groups. These data suggest that
olive leaf extract had a preventive, rather than therapeutic,
effect on hepatic steatohepatitis in SD rats fed a high-fat
diet. The mechanism of this effect is unclear, but anti-
oxidative property of olive leaf extract may play some role
in the preventive effect for the occurrence of NASH.11
Further investigation will be needed to clarify the precise
mechanism of this favorable effect of olive leaf extract on
chronic high-fat diet-induced NAFLD or NASH.
Acknowledgements
The authors thank Mr. Itaru Taniguchi, Mr. Yoshinori
Aoki, and Mr. Taisuke Koike, Eisai Food & Chemical Co.
(Tokyo, Japan), for providing the HFD, LFD and OD diets
and for their helpful advice.
References
1. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver
disease: biochemical, metabolic, and clinical implications. Hepatology
51: 679-689, 2010
2. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and non-
alcoholic steatohepatitis: selected practical issues in their evaluation
and management. Hepatology 49: 306-317, 2009
3. Quercioli A, Montecucco F, Mach F. Update on the treatments of non-
alcoholic fatty liver disease (NAFLD). Cardiovasc Hematol Disord
Drug Targets 9: 261-270, 2009
4. Oh MK, Winn J, Poordad F. Review article: diagnosis and treatment
38
Katsuhisa Omagari et al.: Olive leaf extract in fatty liver
of non-alcoholic fatty liver disease. Aliment Pharmacol Ther 28: 503-
522, 2008
5. Assy N, Nassar F, Nasser G, Grosovski M. Olive oil consumption and
non- alcoholic fatty liver disease. World J Gastroenterol 15: 1809-
1815, 2009
6. Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol
16: 663-678, 2002
7. Tessari P, Coracina A, Cosma A, Tiengo A. Hepatic lipid metabolism
and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 19:
291-302, 2009
8. Hussein O, Grosovski M, Lasri E, Svalb S, Ravid U, Assy N.
Monounsaturated fat decreases hepatic lipid content in non-alcoholic
fatty liver disease in rats. World J Gastroenterol 13: 361-368, 2007
9. Martinez-Gonzalez MA, Sanchez-Villegas A. The emerging role of
Mediterranean diets in cardiovascular epidemiology: monounsaturated
fats, olive oil, red wine or the whole pattern? Eur J Epidemiol 19: 9-
13, 2004
10. Tuck KL, Hayball PJ. Major phenolic compounds in olive oil: metabo-
lism and health effects. J Nutr Biochem 13: 636-644, 2002
11. Omagari K, Kato S, Tsuneyama K, et al. Olive leaf extract prevents
spontaneous occurrence of non-alcoholic steatohepatitis in SHR/NDmcr-
cp rats. Pathology 42: 66-72, 2010
12. Kato S, Omagari K, Tsuneyama K, et al. A possible rat model for non-
alcoholic steatohepatitis: Histological findings in SHR/NDmcr-cp rats.
Hepatol Res 38: 743-744, 2008
13. Omagari K, Kato S, Tsuneyama K, et al. Effect of a long-term high-fat
diet and switching from a high-fat to low-fat, standard diet on hepatic
fat accumulation in Sprague-Dawley rats. Dig Dis Sci 53: 3206-3212,
2008
14. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of
a histological scoring system for nonalcoholic fatty liver disease.
Hepatology 41: 1313-1321, 2005
15. Nakamura H. Thioredoxin and its related molecules: update 2005.
Antioxid Redox Signal 7: 823-828, 2005
16. Burke-Gaffney A, Callister MEJ, Nakamura H. Thioredoxin: friend or
foe in human disease? Trends Pharmacol Sci 26: 398-404, 2005
17. Kelley DS, Nelson GJ, Hunt JE. Effect of prior nutritional status on
the activity of lipogenic enzymes in primary monolayer cultures of rat
hepatocytes. Biochem J 235: 87-90, 1986
18. Daruich J, Zirulnik F, Gimenez MS. Effect of the herbicide glyphosate
on enzymatic activity in pregnant rats and their fetuses. Environment
Res 85: 226-231, 2001
19. Kelley DS, Kletzien RF. Ethanol modulation of the hormonal and nu-
tritional regulation of glucose 6-phosphate dehydrogenase activity in
primary cultures of rat hepatocytes. Biochem J 217: 543-549, 1984
20. Markwell MAK, McGroarty EJ, Bieber LL, Tolbert NE. The subcellular
distribution of carnitine acyltransferases in mammalian liver and kid-
ney. J Biol Chem 248: 3426-3432, 1973
21. Walton PA, Possmayer F. Mg2＋-dependent phosphatidate phosphohydrolase
of rat lung: development of an assay employing a defined chemical
substrate which reflects the phosphohydrolase activity measured using
membrane-bound substrate. Anal Biochem 151: 479-486, 1985
22. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measure-
ment with the folin phenol reagent. J Biol Chem 193: 265-275, 1951
23. Renaud S, de Lorgeril M, Delaye J, et al. Cretan Mediterranean diet
for prevention of coronary heart disease. Am J Clin Nutr 61 (suppl):
1360-1367S, 1995
24. Kok FJ, Kromhout D. Atherosclerosis. Epidemiological studies on the
health effects of a Mediterranean diet. Eur J Nutr 43 (Suppl 1): 1/2-
1/5, 2004
25. Andreadou I, Iliodromitis EK, Mikros E, et al. The olive constituent
oleuropein exhibits anti-ischemic, antioxidative, and hypolipidemic ef-
fects in anesthetized rabbits. J Nutr 136: 2213-2219, 2006
26. Puel C, Mathey J, Agalias A, et al. Dose-response study of effect of
oleuropein, an olive oil polyphenol, in an ovariectomy/inflammation
experimental model of bone loss in the rat. Clin Nutr 25: 859-868,
2006
27. Waterman E, Lockwood B. Active components and clinical applica-
tions of olive oil. Altern Med Rev 12: 331-342, 2007
28. Zarzuelo A, Duarte J, Jimenez J, Gonzalez M, Utrilla MP. Vasodilator
effect of olive leaf. Planta Med 57: 417-419, 1991
29. Gonzalez M, Zarzuelo A, Gamez MJ, Utrilla MP, Jimenez J, Osuna I.
Hypoglycemic activity of olive leaf. Planta Med 58: 513-515, 1992
30. Ruiz-Gutierrez V, Muriana FJG, Maestro R, Graciani E. Oleuropein
on lipid and fatty acid composition of rat heart. Nutr Res 15: 37-51,
1995
31. Bitler CM, Viale TM, Damaj B, Crea R. Hydrolyzed olive vegetation
water in mice has anti-inflammatory activity. J Nutr 135: 1475-1479,
2005
32. Al-Azzawie HF, Alhamdani M-SS. Hypoglycemic and antioxidant ef-
fect of oleuropein in alloxan-diabetic rabbits. Life Sci 78: 1371-1377,
2006
33. Jemai H, Bouaziz M, Fki I, El Feki A, Sayadi S. Hypolipidimic and
antioxidant activities of oleuropein and its hydrolysis derivative-rich
extracts from Chemlali leaves. Chem Biol Interact 176: 88-98, 2008
34. Larter CZ, Yeh MM, Haigh WG, et al. Hepatic free fatty acids accu-
mulate in experimental steatohepatitis: Role of adaptive pathways. J
Hepatol 48: 638-647, 2008
35. Sumida Y, Nakashima T, Yoh T, et al. Serum thioredoxin levels as a
predictor of steatohepatitis in patients with nonalcoholic fatty liver dis-
ease. J Hepatol 38: 32-38, 2003
36. Mitsuyoshi H, Yasui K, Harano Y, et al. Analysis of hepatic genes in-
volved in the metabolism of fatty acids and iron in nonalcoholic fatty
liver disease. Hepatol Res 39: 366-373, 2009
39
40
